A class of oxadiazole sulfoxide compounds containing halogenated benzene, its preparation method and use

A compound and drug technology, applied in the field of drugs related to thrombosis, can solve problems such as high bleeding risk

Active Publication Date: 2016-04-06
邳州德好农产品加工有限公司
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of these drugs is the greater risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A class of oxadiazole sulfoxide compounds containing halogenated benzene, its preparation method and use
  • A class of oxadiazole sulfoxide compounds containing halogenated benzene, its preparation method and use
  • A class of oxadiazole sulfoxide compounds containing halogenated benzene, its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028]

[0029] A. Synthesis of IV-1

[0030] 2.57 g (10 mmol) of compound II-1, 3.70 g (10 mmol) of compound III and 4.15 g (30 mmol) of solid potassium carbonate were stirred overnight in 20 mL of ethanol. The reaction mixture was poured into 200 mL of ice water, stirred, adjusted to pH=4 with concentrated hydrochloric acid, extracted with 50 mL×3 dichloromethane, combined organic phases, washed with brine, dried over anhydrous sodium sulfate, and evaporated the solvent on a rotary evaporator. The obtained residue was purified by column chromatography to obtain pure product IV-1, white solid, MS, m / z=569 ([M+Na] + ).

[0031] B. Synthesis of I-1

[0032] 2.73g (5mmol) of compound IV-1 was dissolved in 25mL of dichloromethane, stirred at -10°C, and 3.13g (20mmol) of m-chloroperoxybenzoic acid (mCPBA) was slowly added. After the reaction mixture was stirred at this temperature for 1 hour, stirring was continued overnight at room temperature. The reaction mixture was pou...

Embodiment 2-10

[0034] According to the method of Example 1, the following compounds with general formula I were synthesized.

[0035]

[0036]

Embodiment 11

[0037] Example 11 In vitro platelet aggregation inhibition test

[0038] Pharmacological tests of substances were performed in TRAP (thrombin receptor activating peptide)-induced platelet aggregation in 96-well plates. Add 3.13% sodium citrate solution to the syringe in advance, then draw 20mL of blood from healthy volunteers, centrifuge at 1500g for 20 minutes, separate the platelet-rich plasma (PRP) and wash it with 1μL PGE1 solution (500μg / mL ethanol solution) / mLPRP for treatment. After incubation at room temperature for 5 minutes, they were centrifuged at 1200 g for 20 minutes to remove leukocytes. Transfer the leukocyte-free PRP to 15 mL PP tubes in batches at 5 mL / portion, and centrifuge at 3600 g to pellet the platelets. Then, decant the upper layer of plasma, resuspend the platelet pellet from 5 mL of PRP in 1 mL of Tyrode (120 mM NaCl, 2.6 mM KCl, 12 mM NaHCO3, 0.39 mM NaH2PO4, 10 mM HEPES, 0.35% BSA, 5.5 mM glucose, pH=7.4) and adjust to Platelet count of 3×105 / μL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of drugs associated with thrombotic diseases, in particular to a category of PAR-1 antagonists of an oxadiazole sulfoxide structure comprising halogeno benzene, a preparation method of the PAR-1 antagonists, and application of drug combinations comprising the halogeno benzene and the halogeno benzene in preparation of the drugs for treating the thrombotic diseases. Please see the formula in the specification, wherein R is selected from halogen substituent groups.

Description

technical field [0001] The invention relates to the field of drugs related to thrombosis diseases. Specifically, the present invention relates to a class of PAR-1 antagonists with a halobenzene-containing oxadiazole sulfoxide structure that has a therapeutic effect on thrombotic diseases, a preparation method thereof, and a pharmaceutical composition containing them. Background technique [0002] Protease Activated Acceptor-1 (PAR-1) is a new target of anti-platelet antithrombotic drugs discovered recently. Protease-activated receptor 1 is also called thrombin receptor. After thrombin is activated by the coagulation chain, it acts on platelets through PAR-1 receptors to activate platelets, causing platelet aggregation and causing thrombus and coagulation. The thrombus induced by PAR-1 is rich in platelet components, which is the main cause of arterial thrombus. PAR-1 antagonists can block thrombin from activating platelets, thereby blocking arterial thrombus formation, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D271/113A61K31/5377A61P7/02A61P9/10
CPCC07D271/113
Inventor 蔡子洋
Owner 邳州德好农产品加工有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap